Small Cap Spotlight Podcast featuring Arch Therapeutics

– Publicwire.com, the number one source for small cap market news, announced today Terrance Norchi,MD, President and CEO of Arch Therapeutics, Inc.(Ticker: ARTH), developer of the AC5 Surgical Hemostat Device ™, is featured on this week’s “Small Cap Spotlight” podcast heard worldwide on Publicwire.com. The interview with host Dave Donlin focuses on Arch Therapeutics flagship product, its initial launch in 2015 in Europe, the $5 Billion market opportunity which is continuing to grow and much more. The interview is part of a new podcast just launched by Publicwire.com, a leading digital financial media company which boasts top rated investor web traffic both in the U.S. and the world (as ranked by Alexa).

The “Small Cap Spotlight” podcast provides valuable insight into today’s financial markets and a unique prospective by featuring company CEOs, authors, newsmakers and many more.  This week’s episode features Arch Therapeutic’s President and CEO Terrance Norch, MD can be found here 

About Arch Therapeutics, Inc.:

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.